Market Overview

UPDATE: Baird Downgrades Align Technology on Valuation Call

Related ALGN
5 Health Care Stocks Hurting From The Affordable Care Act
Align Technology Surges 5% Amid Credit Suisse Upgrade

In a report published Friday, Baird Equity Research analyst Jeff D. Johnson downgraded the rating on Align Technology (NASDAQ: ALGN) from Outperform to Neutral, but reiterated the $49.00 price target.

In the report, Baird Equity Research noted, “Downgrading ALGN to Neutral is not meant to be a call on the company's 3Q, especially as our intra-quarter checks have been generally positive and we still expect modest upside to our/Street's projections this quarter. Further, we continue to like that management has seemingly gone on the offensive recently in both the high- (G4/SmartTrack) and low-acuity (Express 5/Realine) segments of orthodontics.”

Align Technology closed on Thursday at $47.87.

Latest Ratings for ALGN

DateFirmActionFromTo
Oct 2014Goldman SachsUpgradesNeutralBuy
Oct 2014Credit SuisseUpgradesNeutralOutperform
Jul 2014JefferiesMaintainsHold

View More Analyst Ratings for ALGN
View the Latest Analyst Ratings

Posted-In: Baird Equity Research Jeff D. JohnsonAnalyst Color Downgrades Analyst Ratings

 

Related Articles (ALGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters